Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

25. Oktober 2025 11:00 ET | Quelle: Quell TX

Quell Therapeutics to Unveil Promising Data for QEL-005, a Novel CAR-Treg Cell Therapy for Complex Autoimmune Diseases, at ACR Convergence 2025

Results from pre-clinical studies demonstrate immunomodulatory activity of QEL-005 across multiple immune cell lineages involved in complex autoimmune inflammation, including B cells, T cells and...
27. August 2025 07:00 ET | Quelle: Quell TX

Quell Therapeutics Establishes World-Class Scientific Advisory Board

London, UK – 27 August, 2025 – Quell Therapeutics Ltd (“Quell”), a pioneer in engineered T-regulatory (Treg) cell therapies for people with immune-mediated diseases, announces the formation of its...
10. Juni 2025 07:00 ET | Quelle: Quell TX

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease AstraZeneca exercises option to license the first candidate from the IBD joint research...